PML-RARα NQ tested for association with PML-RARα type and white blood cell count in pretreatment samples
| PML-RARα NQ* . | PML-RARα type† . | WBC count‡ . | ||
|---|---|---|---|---|
| L-form . | S-form . | 2000/μL or less . | Greater than 2000/μL . | |
| 10−2-10−1 | 11 | 26 | 18 | 19 |
| 10−3-10−2 | 25 | 2 | 16 | 11 |
| 10−4-10−3 | 1 | 1 | 1 | 1 |
| Total | 37 | 29 | 35 | 31 |
| PML-RARα NQ* . | PML-RARα type† . | WBC count‡ . | ||
|---|---|---|---|---|
| L-form . | S-form . | 2000/μL or less . | Greater than 2000/μL . | |
| 10−2-10−1 | 11 | 26 | 18 | 19 |
| 10−3-10−2 | 25 | 2 | 16 | 11 |
| 10−4-10−3 | 1 | 1 | 1 | 1 |
| Total | 37 | 29 | 35 | 31 |
P was assessed by the 2-sided Wilcoxon rank-sum test.
There was no difference in the GAPDH copy numbers or NQs between the BM and PB samples used for this analysis (P = .643 and P = .320, respectively).
P = < .001. The significantly higher PML-RARα NQs of S-form versus L-form cases were not due to lower GAPDH copy numbers: S-form median 9.3 × 106 (range, 2.9 × 105 to 2.0 × 108); L-form median 8.9 × 106 (range, 3.7 × 105 to 1.3 × 108).
P = .808.